---
title: "董事凯文·比特曼报告出售 Disc Medicine Inc.的普通股"
description: "Disc Medicine, Inc. 的董事 Kevin Bitterman 报告了该公司普通股的处置。完整的文件可以通过提供的链接获取。此消息由公共技术生成，仅供参考，不应被视为财务或法律建议。Disc Medicine Inc. 于 2025 年 8 月 1 日通过 EDGAR 发布了原始内容"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/251249789.md"
published_at: "2025-08-01T20:33:25.000Z"
---

# 董事凯文·比特曼报告出售 Disc Medicine Inc.的普通股

> Disc Medicine, Inc. 的董事 Kevin Bitterman 报告了该公司普通股的处置。完整的文件可以通过提供的链接获取。此消息由公共技术生成，仅供参考，不应被视为财务或法律建议。Disc Medicine Inc. 于 2025 年 8 月 1 日通过 EDGAR 发布了原始内容

Disc Medicine, Inc. 的董事 Kevin Bitterman 报告了该公司普通股的处置。完整的文件可以通过以下链接访问。免责声明：本新闻简报由公共技术公司（PUBT）使用生成性人工智能创建。虽然 PUBT 努力提供准确和及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。Disc Medicine Inc. 于 2025 年 8 月 01 日通过美国证券交易委员会（SEC）运营的电子数据收集、分析和检索系统 EDGAR 发布了用于生成本新闻简报的原始内容（参考 ID：0001415889-25-020863），并对其中包含的信息负全部责任。© 版权 2025 - 公共技术公司（PUBT）原始文件：这里

### Related Stocks

- [IRON.US - Disc Medicine](https://longbridge.com/zh-CN/quote/IRON.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| FDA Delays Disc Medicine's Rare Disease Drug | Disc Medicine Inc. faced a significant stock drop of around 22% following an FDA Complete Response Letter (CRL) regardin | [Link](https://longbridge.com/zh-CN/news/276114804.md) |
| FDA issues complete response letter to Disc Medicine’s bitopertin NDA | The FDA issued a complete response letter (CRL) to Disc Medicine regarding its bitopertin NDA, which sought accelerated  | [Link](https://longbridge.com/zh-CN/news/276055260.md) |
| US FDA declines to approve Disc Medicine's rare disease drug | Feb 13 (Reuters) - Disc Medicinesaid on Friday the U.S. Food and Drug Administration has declined to approve its drug to | [Link](https://longbridge.com/zh-CN/news/275941119.md) |
| FDA Grants Priority Review to Disc Medicine’s Bitopertin NDA | Disc Medicine Inc. has announced that its New Drug Application (NDA) for bitopertin has been accepted for priority revie | [Link](https://longbridge.com/zh-CN/news/272279109.md) |
| Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action | The FDA has delayed its decision on Disc Medicine's rare disease drug, bitopertin, by two weeks to February 10, raising  | [Link](https://longbridge.com/zh-CN/news/272869936.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。